Drug Profile
Insulin oro-buccal spray - Medlab
Alternative Names: NanoCelle Insulin; NanoCelle™ insulin formulationLatest Information Update: 03 Oct 2023
Price :
$50
*
At a glance
- Originator Medlab
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 03 Oct 2023 Discontinued - Preclinical for Diabetes mellitus in Australia (Buccal)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Diabetes-mellitus in Australia (Buccal, Spray)
- 12 Jul 2017 Medlab withdraws a phase 0 trial in Diabetes mellitus (In volunteers) in Australia due to lack of funding, staff or facilities (ACTRN12616001072404)